Novo Nordisk’s Akero Bid Centered On Addressing Cirrhotic MASH

 
• By Joseph Haas
  
breaking news
With its bid for Akero, Novo Nordisk is looking to cover the whole spectrum of MASH therapy (Shutterstock)

More from Deals

More from Business